Loading clinical trials...
Loading clinical trials...
A 12-Week, Randomised, Placebo Controlled, Multi-Centre, Parallel Group Study Assessing the Safety and Tolerability of Nutrifriend Cachexia (Non-Complete Dietary Formula) in Patients With Chronic Obstructive Pulmonary Disease (COPD)
SF-K002 is a pilot study in patients with moderate to severe COPD suffering from involuntary weight loss. The study is 12 weeks, double-blinded, placebo controlled and the main objective is to study the safety and tolerability of Nutrifriend Cachexia.
This study is a 12-week, randomised, parallel group, placebo controlled, multi-centre study. The primary objective is to evaluate the safety and tolerability of Nutrifriend Cachexia in patients with COPD. The secondary objectives of the study are to evaluate effects on body composition, muscle function, daily activity, inflammation, lung function, compliance, appetite and Quality of Life.
Age
50 - No limit years
Sex
ALL
Healthy Volunteers
No
Ladulaas kliniska studier
Borås, Sweden
Pharmasite
Helsingborg, Sweden
Pharmasite
Malmo, Sweden
A+ Science City Site
Stockholm, Sweden
Start Date
May 1, 2015
Primary Completion Date
April 1, 2016
Completion Date
June 1, 2016
Last Updated
December 24, 2020
45
ACTUAL participants
Nutrifriend Cachexia
DIETARY_SUPPLEMENT
Isocaloric placebo
DIETARY_SUPPLEMENT
Lead Sponsor
Smartfish AS
NCT07477600
NCT07462221
NCT07072728
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions